

Special Issue

COVID-19-Related Pulmonary Conditions and Their Treatment

Message from the Guest Editor

This Special Issue, “COVID-19-Related Pulmonary Conditions and Their Treatment”, will mainly focus on coronavirus disease 2019 (COVID-19) and pulmonary conditions caused by COVID-19. COVID-19 is a disease caused by a virus named SARS-CoV-2. Due to its contagiousness, it has quickly spread around the world. Globally, as of 5 January 2023, there have been 657,430,133 confirmed cases of COVID-19, including 6,676,645 deaths, reported to WHO. Most people with COVID-19 have mild symptoms, but some people become severely ill, some of which are severe pulmonary conditions which necessitate mechanical ventilation. A deep understanding of COVID-19-related pulmonary conditions can help us to treat patients with pulmonary conditions. We thus consider this subject to be of particular interest; the topic has the potential to expand biomedicine toward new horizons. We cordially invite authors in the field to submit original research and review articles regarding COVID-19-related pulmonary conditions and their treatment, pertaining to this important and fast-progressing field of biomedicine.

Guest Editor

Dr. Teruya Komatsu

Department of General Thoracic Surgery, National Hospital Organization (NHO) Nagara Medical Center, 1300-7 Nagara, Gifu 502-8558, Japan

Deadline for manuscript submissions

closed (31 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157784

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).